Cargando…

尼妥珠单抗联合化疗二线及以上治疗晚期肺鳞癌

BACKGROUND AND OBJECTIVE EPIDERMAL: growth factor receptor (EGFR) is commonly overexpressed in lung squamous cell carcinoma and has been associated with impaired prognosis. The aim of this study was to observe the efficacy and safety of nimotuzumab, a anti-EGFR monoclonal antibody, combined with che...

Descripción completa

Detalles Bibliográficos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 中国肺癌杂志编辑部 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973415/
https://www.ncbi.nlm.nih.gov/pubmed/27760595
http://dx.doi.org/10.3779/j.issn.1009-3419.2016.10.05
_version_ 1783326626441854976
collection PubMed
description BACKGROUND AND OBJECTIVE EPIDERMAL: growth factor receptor (EGFR) is commonly overexpressed in lung squamous cell carcinoma and has been associated with impaired prognosis. The aim of this study was to observe the efficacy and safety of nimotuzumab, a anti-EGFR monoclonal antibody, combined with chemotherapy as second-or later-line in the treatment of advanced lung squamous cell carcinoma. METHODS: A retrospective analysis of clinical data was conducted in 13 patients with advanced lung squamous cell carcinoma, who were administered with nimotuzumab combined with chemotherapy as second-line or later-line treatment. The efficacy of therapy was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and safety by National Cancer Institute Common Toxicity Criteria (NCI-CTC) 4.0. RESULTS: Of the 13 advanced squamous-cell lung cancer patients, one patient had complete response (CR), 2 patients had partial response (PR), 4 cases had stable disease (SD), and 6 patients had progressive disease. The overall response rate (ORR) was 23.1% and clinical benefit rate (CBR) was 53.8%. EGFR expression were detected by immunohistochemistry in 6 patients and the results showed 5 patients were EGFR 3+ and the other was EGFR 2+. Of these 6 EGFR positive patients, 1 case had CR, 1 case had PR and 4 cases had SD; ORR was 33.3% and CBR was 100.0%. Grade 3/4 hematological toxicities were observed in 3 (23.1%) patients, and non-hametological toxicities were mild. Nimotuzumab-associated skin rash was found in 2 (15.4%) patients. CONCLUSION: Nimotuzumab combined with chemotherapy as second-or later-line therapy for advanced squamous cell lung carcinoma was active and well-tolerated, especially for those patients with EGFR positive.
format Online
Article
Text
id pubmed-5973415
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher 中国肺癌杂志编辑部
record_format MEDLINE/PubMed
spelling pubmed-59734152018-07-06 尼妥珠单抗联合化疗二线及以上治疗晚期肺鳞癌 Zhongguo Fei Ai Za Zhi 肺鳞癌专题 BACKGROUND AND OBJECTIVE EPIDERMAL: growth factor receptor (EGFR) is commonly overexpressed in lung squamous cell carcinoma and has been associated with impaired prognosis. The aim of this study was to observe the efficacy and safety of nimotuzumab, a anti-EGFR monoclonal antibody, combined with chemotherapy as second-or later-line in the treatment of advanced lung squamous cell carcinoma. METHODS: A retrospective analysis of clinical data was conducted in 13 patients with advanced lung squamous cell carcinoma, who were administered with nimotuzumab combined with chemotherapy as second-line or later-line treatment. The efficacy of therapy was evaluated according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and safety by National Cancer Institute Common Toxicity Criteria (NCI-CTC) 4.0. RESULTS: Of the 13 advanced squamous-cell lung cancer patients, one patient had complete response (CR), 2 patients had partial response (PR), 4 cases had stable disease (SD), and 6 patients had progressive disease. The overall response rate (ORR) was 23.1% and clinical benefit rate (CBR) was 53.8%. EGFR expression were detected by immunohistochemistry in 6 patients and the results showed 5 patients were EGFR 3+ and the other was EGFR 2+. Of these 6 EGFR positive patients, 1 case had CR, 1 case had PR and 4 cases had SD; ORR was 33.3% and CBR was 100.0%. Grade 3/4 hematological toxicities were observed in 3 (23.1%) patients, and non-hametological toxicities were mild. Nimotuzumab-associated skin rash was found in 2 (15.4%) patients. CONCLUSION: Nimotuzumab combined with chemotherapy as second-or later-line therapy for advanced squamous cell lung carcinoma was active and well-tolerated, especially for those patients with EGFR positive. 中国肺癌杂志编辑部 2016-10-20 /pmc/articles/PMC5973415/ /pubmed/27760595 http://dx.doi.org/10.3779/j.issn.1009-3419.2016.10.05 Text en 版权所有©《中国肺癌杂志》编辑部2016 https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/
spellingShingle 肺鳞癌专题
尼妥珠单抗联合化疗二线及以上治疗晚期肺鳞癌
title 尼妥珠单抗联合化疗二线及以上治疗晚期肺鳞癌
title_full 尼妥珠单抗联合化疗二线及以上治疗晚期肺鳞癌
title_fullStr 尼妥珠单抗联合化疗二线及以上治疗晚期肺鳞癌
title_full_unstemmed 尼妥珠单抗联合化疗二线及以上治疗晚期肺鳞癌
title_short 尼妥珠单抗联合化疗二线及以上治疗晚期肺鳞癌
title_sort 尼妥珠单抗联合化疗二线及以上治疗晚期肺鳞癌
topic 肺鳞癌专题
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973415/
https://www.ncbi.nlm.nih.gov/pubmed/27760595
http://dx.doi.org/10.3779/j.issn.1009-3419.2016.10.05
work_keys_str_mv AT nítuǒzhūdānkàngliánhéhuàliáoèrxiànjíyǐshàngzhìliáowǎnqīfèilínái
AT nítuǒzhūdānkàngliánhéhuàliáoèrxiànjíyǐshàngzhìliáowǎnqīfèilínái
AT nítuǒzhūdānkàngliánhéhuàliáoèrxiànjíyǐshàngzhìliáowǎnqīfèilínái
AT nítuǒzhūdānkàngliánhéhuàliáoèrxiànjíyǐshàngzhìliáowǎnqīfèilínái
AT nítuǒzhūdānkàngliánhéhuàliáoèrxiànjíyǐshàngzhìliáowǎnqīfèilínái